A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3292-3304

  Hackett, Michael J ^a   Joolakanti, Shyamsunder ^a   Hartranft, Megan E ^a   Guley, Patrick C ^a   Cho, Moo J ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Albumin; Cancer chemotherapy; Endogenous drug delivery systems; Pharmacokinetics; Synthesis

Indexed keywords

3 PENTADECYLGLUTARIC ACID; ALBUMIN; ALIPHATIC DICARBOXYLIC ACID; CREMOPHOR; GLUTARIC ACID; NUCLEOPHILE; PACLITAXEL; SERUM ALBUMIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CYTOSOL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEUTROPENIA; NONHUMAN; TISSUE HOMOGENATE;

EID: 84864041343     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23213     Document Type: Article

References (47)

1. Trissel LA. 1997. Pharmaceutical properties of paclitaxel and their effects on preparation and administration. Pharmacotherapy 17:133S-139S.
2. Hawkins MJ, Soon-Shiong P, Desai N. 2008. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:876-885.
3. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. 2005. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11:4136-4143.
4. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. 2005. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803.
5. Andersen JT, Sandlie I. 2009. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: Implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 24:318-332.
6. Kratz F. 2008. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171-183.
7. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, Heene DL. 1997. Plasma protein (albumin) catabolism by the tumor itself-Implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 26:77-100.
8. Sinn H, Schrenk HH, Friedrich EA, Schilling U, Maier-Borst W. 1990. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int J Rad Appl Instrum B 17:819-827.
9. Schilling U, Friedrich EA, Sinn H, Schrenk HH, Clorius JH, Maier-Borst W. 1992. Design of compounds having enhanced tumour uptake, using serum albumin as a carrier-Part II. In vivo studies. Int J Rad Appl Instrum B 19:685-695.
10. Maeda H. 2010. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug Chem 21:797-802.
11. Schnitzer JE. 1992. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol 262:H246-H254.
12. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. 2006. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324.
13. Young BA, Wang P, Goldblum SE. 1998. The counteradhesive protein SPARC regulates an endothelial paracellular pathway through protein tyrosine phosphorylation. Biochem Biophys Res Commun 251:320-327.
14. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. 2008. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19:899-909.
15. Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW. 1998. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 58:5529-5536.
16. Søreide JA, Lea OA, Kvinnsland S. 1991. Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors. Breast Cancer Res Treat 20:25-32.
17. Andersson C, Iresjö BM, Lundholm K. 1991. Identification of tissue sites for increased albumin degradation in sarcoma-bearing mice. J Surg Res 50:156-162.
18. van der Vusse GJ. 2009. Albumin as fatty acid transporter. Drug Metab Pharmacokinet 24:300-307.
19. Simard JR, Zunszain PA, Hamilton JA, Curry S. 2006. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J Mol Biol 361:336-351.
20. Spector AA. 1975. Fatty acid binding to plasma albumin. J Lipid Res 16:165-179.
21. Cistola DP, Small DM, Hamilton JA. 1987. Carbon 13 NMR studies of saturated fatty acids bound to bovine serum albumin. II. Electrostatic interactions in individual fatty acid binding sites. J Biol Chem 262:10980-10985.
22. Simard JR, Zunszain JR, Ha C-E, Yang JS, Bhagavan NV, Petitpas I, Curry S, Hamilton JA. 2005. Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci U S A 102:17958-17963.
23. Lambert DM. 2000. Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci 11(Suppl 2):S15-S27.
24. Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GC, Swindell CS, Donehower RC, Baker SD. 2003. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: In vitro and clinical pharmacokinetic studies. Clin Cancer Res 9:151-159.
25. Dosio F, Reddy LH, Ferrero A, Stella B, Cattel L, Couvreur P. 2010. Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: Synthesis, characterization, and biological evaluation. Bioconjug Chem 21:1349-1361.
26. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J. 1995. Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312(Pt 3):725-731.
27. Shet J, Desai V, Tilve S. 2004. Domino primary alcohol oxidation-Wittig reaction: Total synthesis of ABT-418 and (E)-4-oxonon-2-enoic acid. Synthesis 35:1859-1863.
28. Shoemaker RH. 2006. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823.
29. Fang Y, Tong GC, Means GE. 2006. Structural changes accompanying human serum albumin's binding of fatty acids are concerted. Biochim Biophys Acta 1764:285-291.
30. Poldy J, Peakall R, Barrow RA. 2008. Pheromones and analogs from Neozeleboria wasps and the orchids that seduce them: A versatile synthesis of 2, 5-dialkylated 1, 3-cyclohexanediones. Tetrahedron Lett 49:2446-2449.
31. Alvarez E, Cuvigny T, du Penhoat CH, Julia M. 1988. Syntheses with sulfones XLIX: Stereo- and enantioselective synthesis of (s)-(-)-3, 9-dimethyl 6-(1-methylethyl) (e)-5, 8-decadien 1-ol acetate, sexual pheromone of yellow scale. Tetrahedron 44:119-126.
32. Buron F, Deguest G, Bischoff L, Fruit C, Marsais F. 2007. On the racemisation of aspartic anhydride during its preparation. Tetrahedron: Asymmetry 18:1625-1627.
33. Deutsch HM, Glinski JA, Hernandez M, Haugwitz RD, Narayanan VL, Suffness M, Zalkow LH. 1989. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J Med Chem 32:788-792.
34. Lin S, Fang K, Hashimoto M, Nakanishi K, Ojima I. 2000. Design and synthesis of a novel photoaffinity taxoid as a potential probe for the study of paclitaxel-microtubules interactions. Tetrahedron Lett 41:4287-4290.
35. Kumar Y, Muzammil S, Tayyab S. 2005. Influence of fluoro, chloro and alkyl alcohols on the folding pathway of human serum albumin. J Biochem 138:335-341.
36. Rosenoer VM. 1977. Albumin structure, function and uses. Pergamon Press. Oxford, United Kingdom.
37. Bertucci C, Cimitan S, Riva A, Morazzoni P. 2006. Binding studies of taxanes to human serum albumin by bioaffinity chromatography and circular dichroism. J Pharm Biomed Anal 42:81-87.
38. Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, Chander MC, Baker SD, He L, Horwitz SB, Swindell CS. 2001. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7:3229-3238.
39. Rice A, Michaelis ML, Georg G, Liu Y, Turunen B, Audus KL. 2003. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J Mol Neurosci 20:339-344.
40. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, Lencer WI, Blumberg RS. 2001. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 166:3266-3276.
41. Peters T. 1985. Serum albumin. Adv Protein Chem 37:161-245.
42. Nyman DW, Campbell KJ, Hersh E, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD. 2005. Phase I and pharmacokinetics Trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785-7793.
43. Xie D, Yao C, Wang L, Min W, Xu J, Xiao J, Huang M, Chen B, Liu B, Li X, Jiang H. 2010. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54:191-196.
44. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. 2010. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 285:4826-4836.
45. Desai N, Yao Z, Trieu V, Soon-Shiong P, Dykes D, Noker P. 2003. Evidence of greater tumor and red cell partitioning and superior antitumor activity of cremophor free nanoparticle paclitaxel (ABI-007) compared to taxol. Proc Am Soc Clin Oncol 22. (abstr 625)
46. Nguyen A, Reyes AE, Zhang M, McDonald P, Wang WLT, Damico LA, Dennis MS. 2006. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 19:291-297.
47. Lichtenbeld HC, Yuan F, Michel CC, Jain RK. 1996. Perfusion of single tumor microvessels: Application to vascular permeability measurement. Microcirculation 3:349-357.